<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30872305</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-4893</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical medicine (London, England)</Title>
          <ISOAbbreviation>Clin Med (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuromyelitis optica spectrum disorders.</ArticleTitle>
        <Pagination>
          <StartPage>169</StartPage>
          <EndPage>176</EndPage>
          <MedlinePgn>169-176</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7861/clinmedicine.19-2-169</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon antibody-mediated disease of the central nervous system. Long segments of spinal cord inflammation (myelitis), severe optic neuritis, and/or bouts of intractable vomiting and hiccoughs (area postrema syndrome) are classic presentations of the disease and may alert the clinician to the diagnosis. Untreated, approximately 50% of NMOSD patients will be wheelchair users and blind, and a third will have died within 5 years of their first attack. Unlike multiple sclerosis, a progressive clinical course is very unusual and the accrual of disability is related to relapses. Approximately 75% of patients have antibodies against aquaporin-4, a water channel expressed on astrocytes. Relapses are treated aggressively to prevent residual disability with high-dose steroids and often plasma exchange. Relapse prevention is crucial and achieved with long-term immunosuppression. In this article we review the pathogenesis, clinical features, diagnosis and management of NMOSD.</AbstractText>
          <CopyrightInformation>© Royal College of Physicians 2019. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huda</LastName>
            <ForeName>Saif</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK shuda@nhs.net.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whittam</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhojak</LastName>
            <ForeName>Maneesh</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chamberlain</LastName>
            <ForeName>Jayne</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Ipsen, Wrexham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noonan</LastName>
            <ForeName>Carmel</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacob</LastName>
            <ForeName>Anu</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Med (Lond)</MedlineTA>
        <NlmUniqueID>101092853</NlmUniqueID>
        <ISSNLinking>1470-2118</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="Y">antibody</Keyword>
        <Keyword MajorTopicYN="Y">aquaporin-4</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30872305</ArticleId>
        <ArticleId IdType="pmc">PMC6454358</ArticleId>
        <ArticleId IdType="doi">10.7861/clinmedicine.19-2-169</ArticleId>
        <ArticleId IdType="pii">19/2/169</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jarius S, Wildemann B.
The history of neuromyelitis optica. J Neuroinflammation
2013;10:8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3599417</ArticleId>
            <ArticleId IdType="pubmed">23320783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Wingerchuk DM, Kryzer TJ, et al. 
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet
2004;364:2106–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, et al. 
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology
2015; 85:177–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitley J, Woodhall M, Waters P, et al. 
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology
2012;79:1273–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22914827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR.
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med
2005;202:473–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verkman AS.
Aquaporins in clinical medicine. Ann Rev Med
2012;63:303–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319404</ArticleId>
            <ArticleId IdType="pubmed">22248325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saadoun S, Papadopoulos MC.
Role of membrane complement regulators in neuromyelitis optica. Mult Scler
2015;21:1644–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25698168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshita Y, Obermeier B, Cotleur AC, et al.
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm
2017;4:e311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5173350</ArticleId>
            <ArticleId IdType="pubmed">28018943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinson SR, Pittock SJ, Lucchinetti CF, et al. 
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology
2007;69:2221–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17928579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinson SR, Roemer SF, Lucchinetti CF, et al. 
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med
2008;205:2473–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2571922</ArticleId>
            <ArticleId IdType="pubmed">18838545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF.
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Annals of the New York Academy of Sciences
2016;1366:20–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4675706</ArticleId>
            <ArticleId IdType="pubmed">26096370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Kessler RA, Rimler Z, et al.
Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm
2018;5:e468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5994702</ArticleId>
            <ArticleId IdType="pubmed">29892608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandit L, Asgari N, Apiwattanakul M, et al. 
Demographic and clinical features of neuromyelitis optica. Mult Scler J
2015;21:845–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4463026</ArticleId>
            <ArticleId IdType="pubmed">25921037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masahiro M, Satoshi K, Fridemann P.
Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry
2018;89:555–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29436488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quek AML, Mckeon A, Lennon VA, et al. 
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol
2012;69:1039–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3746965</ArticleId>
            <ArticleId IdType="pubmed">22507888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bove R, Elsone L, Alvarez E, et al. 
Female hormonal exposures and neuromyelitis optica symptom onset in a multicentre study. Neurol Neuroimmunol Neuroinflamm
2017;4:e339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5366671</ArticleId>
            <ArticleId IdType="pubmed">28382320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matiello M, Kim HJ, Kim W, et al. 
Familial neuromyelitis optica. Neurology
2010;75:310–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2918892</ArticleId>
            <ArticleId IdType="pubmed">20660861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estrada K, Whelan CW, Zhao F, et al. 
A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nature Communications
2018;9:1929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5955905</ArticleId>
            <ArticleId IdType="pubmed">29769526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lennon VA, de Seze J, et al. 
Neuromyelitis optica and non-organ specific autoimmunity. Arch Neurol
2008;65:78–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18195142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob S, Zarei M, Kenton A, et al. 
Gluten sensitivity and neuromyelitis optica: two case reports. J Neurol Neurosurg Psychiatry
2005;76:1028–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739712</ArticleId>
            <ArticleId IdType="pubmed">15965221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Coutinho E, Lana-Peixoto M, et al. 
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology
2012;78:1601–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3348852</ArticleId>
            <ArticleId IdType="pubmed">22551731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Wildemann B, et al. 
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation
2012;9:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3283476</ArticleId>
            <ArticleId IdType="pubmed">22260418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerra H, Pittock SJ, Moder KG, et al. 
Frequency of aquaporin-4 immunoglobulin G in longitudinally extensive transverse myelitis with antiphospholipid antibodies. Mayo Clin Proc
2018;10:1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29655487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Lennon VA, Pittock SJ, et al. 
Revised diagnostic criteria for neuromyelitis optica. Neurology
2006;66:1485–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16717206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsone L, Townsend T, Mutch K, et al. 
Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler J
2012;19:475–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22936333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usmani N, Bedi G, Lam BL, et al. 
Association Between Paroxysmal Tonic Spasms and Neuromyelitis Optica. Arch Neurol
2012;69:121–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22232353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Weinshenker BG, Krecke KN, et al. 
Short myelitis lesions in aquaporin-4-IgG–positive neuromyelitis optica spectrum disorders. JAMA Neurol
2015;72:81–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4552048</ArticleId>
            <ArticleId IdType="pubmed">25384099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duvernoy HM, Risold PY.
The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Research Reviews
2007;56:119–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17659349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kremer L, Mealy M, Jacob A, et al. 
Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler J
2013;20:843–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24099751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanbayashi T, Shimohata T, Nakashima I, et al. 
Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol
2009;66:1563–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20008665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HJ, Friedermann P, Lana-Peixoto MA, et al. 
MRI characteristics of neuromyelitis optica spectrum disorder. Neurology
2015;84:1165–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371410</ArticleId>
            <ArticleId IdType="pubmed">25695963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jury´nczyk M, Tackley G, Kong Y, et al. 
Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry
2016;88:132–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27951522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters PJ, Pittock SJ, Bennett JL, et al. 
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol
2014;5:290–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5102503</ArticleId>
            <ArticleId IdType="pubmed">27840658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid SH, Elsone L, Mutch K, et al. 
The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler
2017;23:228–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27553618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyun J-W, Jeong IH, Joung A, et al. 
Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology
2016;86:1772–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27164713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker BG, Wingerchuk DM, Vukusic S, et al. 
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol
2006;59:566–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16453327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Paul F, Franciotta D, et al. 
Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci
2011;306:82–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21550068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JL, de Seze J, Lana-Peixoto M, et al. 
Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler
2015;21:678–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425816</ArticleId>
            <ArticleId IdType="pubmed">25662342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid SHM, Whittam D, Mutch K, et al. 
What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol
2017;264:2088–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5617862</ArticleId>
            <ArticleId IdType="pubmed">28840314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hacohen Y, Wong YY, Lechner C, et al. 
Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol
2018;75:478–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5885190</ArticleId>
            <ArticleId IdType="pubmed">29305608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jury´nczyk M, Messina S, Woodhall MR, et al. 
Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain
2017;140:3128–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29136091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramanathan S, Prelog K, Barnes EH, et al. 
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J
2016;22:470–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26163068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid S, Whittam D, Saviour M, et al. 
Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin-4 IgG disease. JAMA Neurol
2018;75:65–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5833490</ArticleId>
            <ArticleId IdType="pubmed">29131884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa R, Nakashima I, Takahashi T, et al. 
MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm
2017;4:e322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5241006</ArticleId>
            <ArticleId IdType="pubmed">28105459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hacohen Y, Palace J.
Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology
2018;90:947–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29695599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleiter I, Gahlen A, Borisow N, et al. 
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol
2016;79:206–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26537743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker BG.
What is the optimal sequence of rescue treatments for attacks of neuromyelitis optica spectrum disorder? Ann Neurol
2016;79:204–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26575334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. 
The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology
1999;53:1107–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10496275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Wingerchuk DM, Palace J, et al. 
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol
2014;71:324–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24445513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Leite I, Jacob A.
A practical guide to the treatment of neuromyelitis optica. Pract Neurol
2012;12:209–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22869762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S-H, Huh S-Y, Lee SJ, et al. 
A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol
2013;70:1110–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23897062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tallantyre EC, Whittam DH, Jolles S, et al. 
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol
2018;265:1115–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5937879</ArticleId>
            <ArticleId IdType="pubmed">29511864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min J-H, Kim BJ, Lee KH.
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal
2011;18:113–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22146605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob A, Hutchinson M, Elsone L, et al. 
Does natalizumab therapy worsen neuromyelitis optica? Neurology
2012;79:1065–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22914835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Leite MI, Nairne, et al. 
Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol
2010;67:1016–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20697055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanamori Y, Nakashima I, Takai Y, et al. 
Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology
2011;77:652–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21813781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chavarro VS, Mealy MA, Simpson A, et al. 
Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm
2016;3:e286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5079380</ArticleId>
            <ArticleId IdType="pubmed">27800532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Business Wire 
Alexion announces successful Phase 3 PREVENT study of Soliris® (Eculizumab) in patients with neuromyelitis optica spectrum disorder (NMOSD). Business Wire. www.businesswire.com/news/home/20180924005 283/en/Alexion- Announces-Successful-Phase-3-PREVENT-Study [Accessed 6 November 2018].</Citation>
        </Reference>
        <Reference>
          <Citation>Whittam D, Hamid S, Linaker S.
et al.
Relapse rates and disability in the modern treatment era of neuromyelitis optica: data from a specialised UK centre. Paris: 7th joint ECTRIMS–ACTRIMS meeting, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Whittam D, Wilson M, Hamid S, et al. 
What’s new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol
2017;264:2330–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28289845</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
